- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04144127
Soccer Intervention in Prostate Cancer Survivors
A Soccer-based Lifestyle Intervention vs mHealth-based Physical Activity Intervention to Improve Bone Health and Metabolic Health in Prostate Cancer Survivors
Study Overview
Detailed Description
Prostate cancer (PCa) is the most common cancer in men in the U.S. and in other industrialized countries. The lifetime probability of PCa in males is one in nine, and it has a high economic burden, with costs expected to rise. Modern tailored treatment approaches, including androgen deprivation therapy (ADT), have resulted in longer life expectancy, but also longer treatment periods, which lead to significant adverse side effects. These often include decreased bone mineral density (BMD), increased risk of fractures, low functional capacity, loss of lean body mass (LBM), increased fat mass, insulin resistance, psychological distress and pain. Of particular concern is a sharp decline in bone health, with systemic bone loss caused by PCa-produced osteoclastogenic cytokines and drug interventions. Independent of disease stage, fractures in PCa patients are predictors of survival. In addition, concomitant physical inactivity and stress during and after treatment predispose PCa patients to elevated risk of deconditioning, BMD loss, cardiovascular and metabolic disease morbidity and mortality.
Exercise-based lifestyle interventions aimed at counteracting treatment-induced adverse effects have been shown to be safe and effective in improving bone, functional and cardiometabolic health for patients with PCa. However, men, in general, are harder to engage in physical activity (PA) and lifestyle interventions. As an alternative to traditional exercise programs, recreational team sports provide a unique environment that may lead to increased physical activity participation and motivation to engage in other lifestyle changes. More than any other sport, recreational soccer (RS) has been shown to be a successful health intervention in patients with, or at risk of chronic diseases, including PCa.
Leveraging the growing enthusiasm around soccer in Atlanta and the U.S. may lead to increased interest, participation, retention and engagement in lifestyle change programming among PCa survivors. Therefore, this study seeks to directly test the implementation feasibility of a soccer-based lifestyle change intervention to determine the effect on bone health, body composition, mental health, functional and cardiometabolic status among PCa survivors.
Participants will be offered an intensive intervention including RS programming and lifestyle education. The group will receive RS, consisting of conditioning drills and games, adapted to the population during 60-minute sessions twice per week. The researchers will evaluate health outcomes at baseline and after 3 months of the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- men aged 18-79 years
- PCa survivors that had at least 6 months of hormone therapy (i.e. ADT with testosterone lowering agents) within the past 10 years
- not engaged in soccer practice or other exercise or lifestyle intervention program for the past 12 months
- availability of smartphone to receive text messages
- treating Oncologist clearance
- ability to read in English or Spanish and provide informed consent
Exclusion Criteria:
- BMI > 40 kg/m^2
- resting BP ≥170/100 at screening or uncontrolled hypertension
- any mobility issues or exercise program contraindications
- a recent (i.e., within 12 months) myocardial infarction, diagnosis of congestive heart disease, other active cancer
- bone or organ metastases
- chemotherapy within past 6 months
- therapies and diseases of bone unrelated to PCa e.g. systemic glucocorticoids, bisphosphonates, teriparatide, denosumab, osteomalacia; osteosarcoma; Paget's disease; systemic lupus erythematosus; inflammatory bowel diseases, rheumatoid arthritis; thyroid/parathyroid disorder or mental illness
- not coronavirus disease 2019 (COVID-19) vaccinated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Soccer Group
Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week).
They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics).
During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate.
All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lumbar Spine Bone Mineral Density (BMD)
Time Frame: Baseline, 3 months post-intervention
|
Bone mineral density will be measured by dual x-ray absorptiometry (DXA) scan at the lumbar spine (L2-L4).
Decreased BMD a is associated with an increased risk of fractures.
|
Baseline, 3 months post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Hip BMD
Time Frame: Baseline, 3 months post-intervention
|
Bone mineral density will be measured by dual x-ray absorptiometry (DXA) scan at the hip.
Decreased BMD a is associated with an increased risk of fractures.
|
Baseline, 3 months post-intervention
|
|
Osteocalcin Level
Time Frame: Baseline, 3 months post-intervention
|
Osteocalcin is marker of bone formation.
The normal range for osteocalcin varies by lab and elevated levels are seen in patients with bone diseases characterized by increased bone turnover.
|
Baseline, 3 months post-intervention
|
|
C-terminal Telopeptide of Collagen (CTx)
Time Frame: Baseline, 3 months post-intervention
|
C-terminal telopeptide of collagen (CTx) is a bone resorption marker.
Increased levels indicate increased bone resorption with conditions such as osteoporosis and osteopenia.
|
Baseline, 3 months post-intervention
|
|
Weight
Time Frame: Baseline, 3 months post-intervention
|
Weight is measured in kilograms (kg).
|
Baseline, 3 months post-intervention
|
|
Body Mass Index (BMI)
Time Frame: Baseline, 3 months post-intervention
|
Body Mass Index (BMI) is weight in kilograms divided by the square of height in meters.
|
Baseline, 3 months post-intervention
|
|
Percentage of Body Fat
Time Frame: Baseline, 3 months post-intervention
|
Body fat is measured by dual x-ray absorptiometry (DXA) scan.
|
Baseline, 3 months post-intervention
|
|
Waist Circumference
Time Frame: Baseline, 3 months post-intervention
|
Waist circumference is measured in centimeters (cm).
|
Baseline, 3 months post-intervention
|
|
Lean Body Mass
Time Frame: Baseline, 3 months post-intervention
|
Lean body mass is body weight minus weight from body fat.
|
Baseline, 3 months post-intervention
|
|
Resting Heart Rate
Time Frame: Baseline, 3 months post-intervention
|
The normal resting heart rate in adults is between 60 and 100 beats per minute (bpm).
A lower resting heart rate indicates that the person has better fitness as the heart is working more efficiently.
|
Baseline, 3 months post-intervention
|
|
Systolic Blood Pressure
Time Frame: Baseline, 3 months post-intervention
|
Systolic blood pressure (BP) will be measured while sitting using a calibrated electronic blood pressure sphygmomanometer at Baseline and at 3 months post-intervention.
A normal systolic blood pressure reading is lower than 120 mmHg.
BP values higher than 120 mmHg correlate with worse outcome.
|
Baseline, 3 months post-intervention
|
|
Diastolic Blood Pressure
Time Frame: Baseline, 3 months post-intervention
|
Diastolic blood pressure (BP) will be measured while sitting using a calibrated electronic blood pressure sphygmomanometer prior to any activity (Baseline) and at 3 months post-intervention.
A normal diastolic blood pressure reading is lower than 80 mmHg.
BP values higher than 80 mmHg correlate with worse outcome.
|
Baseline, 3 months post-intervention
|
|
Aerobic Capacity
Time Frame: Baseline, 3 months post-intervention
|
Aerobic capacity is measured by 6 minute walk test distance (meters).
|
Baseline, 3 months post-intervention
|
|
Muscle Strength
Time Frame: Baseline, 3 months post-intervention
|
Muscle strength is measured as hand grip strength (kg).
Hand grip was measured using a study approved dynamometer to test the maximum isometric strength of the hand and forearm muscles of the dominant hand.
An increase in values means that grip strength is improving.
|
Baseline, 3 months post-intervention
|
|
Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2) Score
Time Frame: Baseline, 3 months post-intervention
|
Physical activity self-efficacy is assessed with the BREQ-2 instrument.
The BREQ-2 has 19 items measuring motivation to exercise, with 5 motivational styles examined: intrinsic regulation (the respondent finds physical activity enjoyable), identified regulation (the respondent sees benefits of physical activity), introjected regulation (physical activity is done to increase self-esteem or avoid negative feelings with not performing exercise), external regulation (physical activity is done based on rewards or punishments from someone else), and amotivation (the respondent has no motivation to engage in physical activity).
Responses are given on a 5 point Likert scale where 0=not true for me, and 4=very true for me.
A relative autonomy index (RAI) can be calculated by weighting the scores for each motivational style factor.
The weights range from 3 to -3 and total RAI scores range from -24 to 20.
Higher scores indicate greater self-determined motivation to engage in physical activity.
|
Baseline, 3 months post-intervention
|
|
Dietary Intake
Time Frame: Baseline, 3 months post-intervention
|
The dietary intake is measured using the Nutrition Database System for Research (NDSR) 24-hour dietary recall.
The NDSR is a dietary analysis software application used to collect and calculate nutritional intake.
|
Baseline, 3 months post-intervention
|
|
Number of Participants Smoking Cigarettes
Time Frame: Baseline, 3 months post-intervention
|
Smoking habits are assessed with the National Health and Nutrition Examination Survey (NHANES) 2019-2020 for smoking and tobacco use.
This instrument includes 24 items and the number of questions that a respondent answers depends on their past and current smoking behaviors.
Participants are asked if they currently smoke cigarettes and possible responses are: "every day", "some days", and "not at all".
|
Baseline, 3 months post-intervention
|
|
Alcohol Habits
Time Frame: Baseline, 3 months post-intervention
|
Number of alcohol beverages per week will be recorded.
|
Baseline, 3 months post-intervention
|
|
Sleep Time
Time Frame: Baseline, 3 months post-intervention
|
Average sleep time will be collected in minutes per day.
|
Baseline, 3 months post-intervention
|
|
Weekly Steps
Time Frame: Baseline, 3 months post-intervention
|
Participants will be asked to wear a Garmin fitness tracker throughout the study and physical activity will be measured as steps taken per week.
|
Baseline, 3 months post-intervention
|
|
SF-12 Health Survey Score
Time Frame: Baseline, 3 months post-intervention
|
Quality of life is assessed with the SF-12 Health Survey.
The SF-12 is a multipurpose, standardized self-report short form survey with 12 questions assessing mental and physical functioning.
The SF-12 consists of 12 items with a Likert-type response format that measures quality of life with a Physical Component Summary (PCS) and Mental Component Summary (MCS).
Subscales associated with the PCS include physical functioning, role limitations due to physical problems, bodily pain, and general health perceptions.
Subscales associated with the MCS include vitality (energy and fatigue), social functioning, role limitations due to emotional problems, and mental health.
A scoring algorithm is used to generate a total score for each component ranging from 0 to 100.
Low values represent a poor health state while high values represent a good health state.
|
Baseline, 3 months post-intervention
|
|
Center for Epidemiologic Studies Depression Scale (CESD) Score
Time Frame: Baseline, 3 months post-intervention
|
Symptoms of depression are assessed with the CESD.
The CESD is a 20-item questionnaire asking about feelings and behaviors during the past week.
Responses are given on a 4-point scale where 0 = rarely or none of the time (less than 1 day), 1 = some or a little of the time (1-2 days), 2 = occasionally or a moderate amount of time (3-4 days), and 3 = most or all of the time (5-7 days).
Scores range from 0 to 60 with high scores indicating greater depressive symptoms.
|
Baseline, 3 months post-intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Roberto Felipe Lobelo, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00110890
- P30CA138292 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Washington University School of MedicineThe Society of Nuclear Medicine and Molecular ImagingNot yet recruitingRecurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer MetastaticUnited States
Clinical Trials on Soccer
-
Children's Hospital of PhiladelphiaCompleted
-
Indiana UniversityCompleted
-
Fan MaoCompletedPerformance | Motor Development | Soccer Training | Executive Function (Cognition)China
-
University of Southern DenmarkUniversity of CopenhagenCompletedMental Health Wellness 1Denmark
-
Indiana UniversityCompletedConcussion, MildUnited States
-
Indiana UniversityCompleted
-
Leach Chiropractic ClinicMississippi University for Women; MUW Southern Women's InstituteCompleted
-
Indiana UniversityCompletedAttention-deficit/Hyperactivity Disorder | Sport InjuryUnited States
-
Instituto de Cardiologia de Santa CatarinaCompletedCoronary Artery DiseaseBrazil
-
University of OviedoActive, not recruiting